Program
GKL-006RTU
A development code. Also written as “GKL-006RTU injection”.
Its studies are mostly in Acute Lung Injury, led by Beijing Gene Key Life Technology.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Beijing Gene Key Life Technology | 11 open or running | phase 2since Jun 29, 2026 | Jun 29, 2026 | Dec 30, 2028phase 2 · NCT07706855 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 29, 2026First study: phase 2 study in Acute Lung InjuryFirst studyNCT07706855 · 52 planned
- Sep 30, 2026Primary completion moved from 2027-07-30 to 2028-12-30Date moved laterphase 2 · +17 months · NCT07706855
Ahead
- Dec 30, 2028Primary completion: phase 2 study in Acute Lung InjuryNCT07706855
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07706855Acute Lung Injury | 2 | Not yet recruiting | Dec 30, 2028 | 52 |
How it is read
Names in the registry
- “GKL-006RTU injection”, 1 entry
Codes read as this program: GKL006RTU.
Conditions, from the studies’ own filings
- Acute Lung Injury, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.